Patel Dinesh V PH D's Form 4 filing
Protagonist Therapeutics, Inc (PTGX) · filed Sep 10, 2026
- Accession no.
- 0001104659-26-106831
- Filed
- Sep 10, 2026, 9:17 PM ET
- Trade date
- Sep 8-10, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 3 derivative transactions. Open-market sales total $18.2M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Patel Dinesh V PH DCIK 0001120477 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Common Stock | MOption exerciseAcquired | +54,174 | $21.58 | +$1,169,074.92 | 577,142 | Direct | |
| Sep 8, 2026 | Common Stock | SSaleDisposed | −54,174 | $145.87F2 | −$7,902,361.38 | 522,968 | Direct | |
| Sep 9, 2026 | Common Stock | MOption exerciseAcquired | +63,548 | $21.58 | +$1,371,365.84 | 586,516 | Direct | |
| Sep 9, 2026 | Common Stock | SSaleDisposed | −63,548 | $146.18F3 | −$9,289,446.64 | 522,968 | Direct | |
| Sep 10, 2026 | Common Stock | MOption exerciseAcquired | +7,278 | $21.58 | +$157,059.24 | 530,246 | Direct | |
| Sep 10, 2026 | Common Stock | SSaleDisposed | −7,278 | $144.10F4 | −$1,048,759.8 | 522,968 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Common Stock | MOption exerciseDisposed | −54,174 | $0.00 | $0 | 70,826 | Direct | |
| Sep 9, 2026 | Common Stock | MOption exerciseDisposed | −63,548 | $0.00 | $0 | 7,278 | Direct | |
| Sep 10, 2026 | Common Stock | MOption exerciseDisposed | −7,278 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.00 to $147.29. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $144.49 to $151.27. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.51 to $145.19. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.